Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bionik Laboratories Corp. (OTC: BNKL).

Full DD Report for BNKL

You must become a subscriber to view this report.


Recent News from (OTC: BNKL)

Bionik Laboratories Issues Letter to Stockholders
TORONTO and BOSTON , April 3, 2018 /PRNewswire/ --   Bionik Laboratories Corp . (OTCQB: BNKL) ("Bionik" or the "Company"), a global robotics company focused on providing rehabilitation and assistive technology solutions from hospital to home for individuals with neurological a...
Source: PR Newswire
Date: April, 03 2018 17:42
Bionik Laboratories Appoints Peter Gerald Malone and Joseph Martin to its Board of Directors
TORONTO and BOSTON , March 20, 2018 /PRNewswire/ --   Bionik Laboratories Corp . (OTCQB: BNKL) ("Bionik" or the "Company"), a global robotics company focused on providing rehabilitation and assistive technology solutions from hospital to home for individuals with neurological ...
Source: PR Newswire
Date: March, 20 2018 07:32
Bionik Laboratories Corp. and Curexo Enter Exclusive Distribution Agreement for Sale of Robotic Rehabilitation Systems in U.S. and South Korea
TORONTO and BOSTON , March 7, 2018 /PRNewswire/ --  Bionik Laboratories Corp . (OTCQB: BNKL) ("Bionik" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions from hospital to home for individuals with neurological and mobility c...
Source: PR Newswire
Date: March, 07 2018 07:32
Bionik Laboratories reports Q3 results
Bionik Laboratories ( OTCQB:BNKL ): Q3 EPS of -$0.03 More news on: Bionik Laboratories Corp., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: February, 13 2018 16:36
Bionik Laboratories Reports Third Quarter Fiscal Year 2018 Financial Results
TORONTO and BOSTON , Feb. 13, 2018 /PRNewswire/ --  Bionik Laboratories Corp . (OTCQB: BNKL) ("Bionik" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital...
Source: PR Newswire
Date: February, 13 2018 16:02
Bionik launches improved version of InMotion Arm robotic system
Bionik Laboratories ( OTCQB:BNKL -8.7% ) launches the newest version of its InMotion Arm interactive robotic system designed for clinical rehabilitation of stroke survivors and patients with mobility impairments due to neurological conditions. More news on: Bionik Laboratories Corp.,...
Source: SeekingAlpha
Date: February, 05 2018 10:15
Bionik Laboratories Corp. Launches New Commercial Generation InMotion Arm Robotic System to Improve Rehabilitation for Stroke Survivors
TORONTO and BOSTON , Feb. 5, 2018 /PRNewswire/ -- Bionik Laboratories Corp . (OTCQB: BNKL) ("Bionik" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility impairments from hospital to h...
Source: PR Newswire
Date: February, 05 2018 07:31
Bionik Laboratories Corp. Appoints Andre Auberton-Herve as Chairman of Board of Directors
TORONTO and BOSTON , Jan. 29, 2018 /PRNewswire/ -- Bionik Laboratories Corp . (OTCQB: BNKL) ("Bionik" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility impairments from hospital to ...
Source: PR Newswire
Date: January, 29 2018 07:32
Bionik Laboratories reports Q2 results
Bionik Laboratories ( OTCQB:BNKL ): Q2 EPS of -$0.04 More news on: Bionik Laboratories Corp., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 14 2017 07:40
Bionik Laboratories Reports Second Quarter Fiscal Year 2018 Financial Results
Bionik Laboratories Reports Second Quarter Fiscal Year 2018 Financial Results Canada NewsWire TORONTO and BOSTON, Nov. 14, 2017 TORONTO and BOSTON , Nov. 14, 2017 /CNW/ -- Bionik Laboratories Corp . (OTCQB: BNKL) ("Bionik" or the "Company"), a robotics company focus...
Source: Canada Newswire
Date: November, 14 2017 07:32

 


About Bionik Laboratories Corp. (OTC: BNKL)

Logo for Bionik Laboratories Corp. (OTC: BNKL)

lt p gt Bionik Laboratories is a global, pioneering robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological disorders. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and paraplegic patients including three products on the market and four products under varying stages of development. The InMotion Systems the InMotion Arm, InMotion Wrist, InMotion Hand and InMotion Ankelbot are designed to provide intelligent, patient adaptive therapy in a manner that has been clinically verified to maximize neuro recovery. Bionik is also developing a lower body exoskeleton, ARKE designed to allow paraplegics as well as wheelchair users the ability to rehabilitate through walking. lt /p gt

 

 

 

Current Management

  • Eric Dusseux / CEO
    • Dr. Eric Michel Dusseux was made Chief Executive Officer on September , and he is also a Director since July , . He was previously the President Europe at Auregen BioTherapeutics SA and was a director at Auregen BioTherapeutics Inc., which is translating D bioprinting technology for innovative treatments for patients with rare disorders, since February . Prior to that, from November through January , Dr. Dusseux was President Europe at Bemido SA, a family office. From September to October , Dr. Dusseux was an Executive Committee Member in the Corporate Strategy Department of Sanofi Pasteur SA, the vaccines division of Sanofi, a global healthcare leader, where he led corporate strategy, business intelligence, and international business development. He has also served in key roles at GlaxoSmithKline Biologicals from January to June , leading product development and business growth strategy. Dr. Dusseux also gained significant experience providing strategic advice for numerous pharmaceutical, medical device, payer and biotechnology clients, while working for the Boston Consulting Group from to .
  • Leslie Markow / CFO, IR
    • Ms. Markow has served as the Company s parttime Chief Financial Officer since September . Ms. Markow holds a CPA and CA in Canada, a US CPA Illinois and Chartered Director designations. Ms. Markow has acted as Chief Financial Officer of Stewardship Ontario and Blue Ocean NutraSciences Inc. She has acted as Director of Client Service for Resources Global Professionals, a Nasdaqlisted global consulting firm. For years she held various positions at SunOpta Inc. a Nasdaq/TSX listed public company, Chief Administrative Officer, VicePresident Regulatory Reporting amp Compliance, Chief Financial Officer and VicePresident,Finance and Controller. Ms. Markow started her career in with PricewaterhouseCoopers, ultimately holding a position as Senior Audit Manager. She is a member of the Board of Directors and Chairperson of the Audit Committee of Jemtec Inc. She also is a member of Financial Executives Canada, where she is a past National Board Director, Toronto Board Director, Toronto Chapter President and the winner of the Toronto Leadership Aware, and is a faculty member of The Directors College, which is a joint venture of McMaster University and The Conference Board of Canada.
  • Michal Prywata / CTO, Founder
    • Michal Prywata is the cofounder of Bionik Laboratories and has served as the company s Chief Operating Officer since March , and was previously the company s Chief Executive Officer. He has a passion for developing technology, which was evident from a very young age. Mr. Prywata has studied biomedical engineering and has an impressive track record of winning technology showcases and inventing. Equally impressive is his very strong understanding of developing technologies that address significant and untapped markets, and turning them into products. Over the past years he has founded the company, raised and secured the initial capital, and turned numerous concepts into products. Mr. Prywata is the coinventor and writer of current intellectual property in the company.
  • Tim McCarthy / Chief Commercial Officer
    • Mr. McCarthy was made Chief Commercialization Officer in August . From January to July , he was the CEO of Medical Compression Systems, Inc., a medical device company developing smart compression treatments that enhance circulation, where he led a commercial stabilization and turnaround effort in order to prepare it for a merger amp acquisition transaction in . From December to May , he was the President and CEO of iWalk Inc., a medical robotics company commercializing the M.I.T. invented BiOM T System an actively powered lower limb bionic prosthesis to normalize gait. From April through November , he held various positions at Ossur Americas formerly Flex Foot , a leading global company in noninvasive orthopedics, culminating in the position of Vice President of Sales and Marketing . From January to March , he was a Vice President/Principal of Northeast Rehab, Inc. and OMEX, Inc., a regional distributor of postoperative orthopedic rehabilitation products and DME billing services. From through , he was first Area Sales Manager and then Regional Sales Manager for The Chattanooga Group, Inc., which represents itself as the world s largest manufacturer of rehabilitation products for the treatment of orthopedic, neurological, and soft tissue disorders. Mr. McCarthy graduated cum laude from Northeastern University with a BS in Business Administration, and his MBA from the University of California, Los Angeles.
  • AndreJacques AubertonHerve / Chairman
    • Andre AubertonHerve was made Chairman on January , .Mr. AubertonHerve is the founder of A Consulting amp Engineering A Consulting , which provides strategic advice and consulting services with respect to renewable energy and digital innovation, and has served as its President and CEO since its founding in July . A Consulting has been providing consulting services to the Company since February . Mr. AubertonHerve cofounded Soitec SA, a publicly traded company on the Euronext Paris stock exchange which designs and manufactures innovative semiconductor materials which are used in many smartphone platforms and computing activities, where he was President and CEO from July until January , then Chairman and Chairman Emeritus since September . While at Soitec SA, Mr. AubertonHerve was responsible for overseeing the strategic, operational and financial activities of the company. He was responsible for building an international high tech group in ten countries and five manufacturing facilities in Europe, Asia and the U.S. Mr. AubertonHerve also led the company through its listing on Euronext in , raising more than billion since then with some of the world s largest investment banks. He has been nominated Knight of the Legion of Honor and Knight of the Order of Merit in France. Mr. AubertonHerve holds a Doctorate degree in Semiconductor Physics and a Master s degree in Materials Science from Ecole Centrale de Lyon in France.
  • Peter Bloch /
    • Mr. Bloch has served as the Company s Chief Executive Officer since March , and was previously the company s Chief Financial Officer. Mr. Bloch is a Chartered Accountant with a track record of building both public and private technology companies, mainly in the Life Sciences industry. His past years of executive management experience includes CFO and Joint Interim CEO of Sanofi Canada Inc., CFO of Intellivax and Founder of Tribute Pharmaceuticals. Mr. Bloch also served as CFO of Gennum and Just Energy, both TSX listed Companies. These companies have ranged in size from startups to revenues of over billion. In these roles Mr. Bloch has secured significant funding for both private and public companies, including experience with Initial Public Offerings. He has also led a number of acquisitions and partnerships. Mr. Bloch has been on a number of both public and private company s board of directors.
  • Remi Gaston Dreyfus / Independent Director
    • Remi Gaston Dreyfus: Director. Mr. Dreyfus has been a director of the Company since September , . Since , Mr. Dreyfus has been board member of the auction company Christie s in Paris. Since , Mr. Dreyfus has been the CEO and Founder of RGD Investissements S.A.S. in Paris, a developer of and investor in real estate assets in Paris. Prior to , Mr. Dreyfus was a shareholder, Chairman and CEO of the PhotoJournalism group A.G.I. including Gamma Press Agency . Mr. Dreyfus was a cofounder of a Parisian law firm in , and was a French lawyer until . Remi Gaston Dreyfus: Director. Mr. Dreyfus has been a director of the Company since September , . Since , Mr. Dreyfus has been board member of the auction company Christie s in Paris. Since , Mr. Dreyfus has been the CEO and Founder of RGD Investissements S.A.S. in Paris, a developer of and investor in real estate assets in Paris. Prior to , Mr. Dreyfus was a shareholder, Chairman and CEO of the PhotoJournalism group A.G.I. including Gamma Press Agency . Mr. Dreyfus was a cofounder of a Parisian law firm in , and was a French lawyer until . We believe that Mr. Dreyfus is qualified to serve as a member of the Board of Directors due to his experience as a director of Christie s, his legal training, and his experience as a real estate investor.
  • Eric Dusseux /
    • Dr. Eric Michel Dusseux was made Chief Executive Officer on September , and he is also a Director since July , . He was previously the President Europe at Auregen BioTherapeutics SA and was a director at Auregen BioTherapeutics Inc., which is translating D bioprinting technology for innovative treatments for patients with rare disorders, since February . Prior to that, from November through January , Dr. Dusseux was President Europe at Bemido SA, a family office. From September to October , Dr. Dusseux was an Executive Committee Member in the Corporate Strategy Department of Sanofi Pasteur SA, the vaccines division of Sanofi, a global healthcare leader, where he led corporate strategy, business intelligence, and international business development. He has also served in key roles at GlaxoSmithKline Biologicals from January to June , leading product development and business growth strategy. Dr. Dusseux also gained significant experience providing strategic advice for numerous pharmaceutical, medical device, payer and biotechnology clients, while working for the Boston Consulting Group from to .
  • Dr. Robert Hariri / Independent Director
    • Bob Hariri is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace. Dr. Hariri is the Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics, one of the world s largest human cellular therapeutics companies. Dr. Hariri has pioneered the use of stem cells to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering. His activities and experience includes academic neurosurgeon at Cornell, businessman, military surgeon and aviator and aerospace innovator. Dr. Hariri has over issued and pending patents, has authored over published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of TNF tumor necrosis factor . Dr. Hariri was recipient of the Thomas Alva Edison Award in and , The Fred J. Epstein Lifetime Achievement Award and has received numerous other honors for his many contributions to biomedicine and aviation. Dr. Hariri also serves on numerous Boards of Directors including Myos Corporation and Provista Diagnostics. Dr. Hariri is an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine and a member of the Board of Visitors of the Columbia University School of Engineering amp Applied Sciences and the Science amp Technology Council of the College of Physicians and Surgeons, and is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X PRIZE Foundation. Dr. Hariri is also a Trustee of the Liberty Science Center and has been appointed Commissioner of Cancer Research by NJ Governor Christie. Dr. Hariri is a member of the Board of Trustees of the J. Craig Venter Institute.
  • Marc Marthieu / Independent Director
    • Mr. Mathieu has been the U.S. Chief Marketing Officer of Samsung North America since June . Prior to that, from April to June , he was Senior Vice President of Global Marketing at Unilever, where he was responsible for the development of Unilever s global marketing strategy. Mr. Mathieu has also overseen the implementation of pivotal programs such as Project Sunlight, the first Unilever brand consumer initiative to motivate millions of people to adopt more sustainable lifestyles, and The Unilever Foundry, a platform that provides a single entrypoint for innovative startups seeking to partner with Unilever. Since January , Mr. Mathieu has been the Chairman and Cofounder of We amp Co, a social app for People who provide and enjoy great service. From January through August , Mr. Mathieu founded and was principal of the strategic brand consultancy, BeDo, which worked to build brands with purpose and fuse marketing and sustainability agendas. From through , Mr. Mathieu held various positions at CocaCola, culminating in Senior Vice President Global Brand Marketing. He sits on the Advisory Panel of the Guardian Digital and Media network and writes for Marketing Week magazine. He is a regular conference and keynote speaker on themes such as the Future of Marketing. Mr. Mathieu has a passion for theatre and sits on the Board of Directors for the Almeida Theatre and Punchdrunk.
  • Michal Prywata /
    • Michal Prywata is the cofounder of Bionik Laboratories and has served as the company s Chief Operating Officer since March , and was previously the company s Chief Executive Officer. He has a passion for developing technology, which was evident from a very young age. Mr. Prywata has studied biomedical engineering and has an impressive track record of winning technology showcases and inventing. Equally impressive is his very strong understanding of developing technologies that address significant and untapped markets, and turning them into products. Over the past years he has founded the company, raised and secured the initial capital, and turned numerous concepts into products. Mr. Prywata is the coinventor and writer of current intellectual property in the company.

Current Share Structure

  • Market Cap: $3,911,975 - 03/09/2018
  • Authorized: 200,000,000 - 03/01/2018
  • Issue and Outstanding: 55,885,357 - 03/01/2018
  • Float: 55,885,357 - 01/02/2018

 


Recent Filings from (OTC: BNKL)

Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: May, 08 2018
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (OTC: BNKL)

Daily Technical Chart for (OTC: BNKL)


Stay tuned for daily updates and more on (OTC: BNKL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BNKL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BNKL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BNKL and does not buy, sell, or trade any shares of BNKL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/